Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCR in children with high-risk neuroblastoma. In the present study, a single arm trial of tandem HDCT/ASCR will be carried out. In the present study, the investigators will investigate whether tandem HDCT/ASCR might improve the survival of patients with high-risk neuroblastoma with acceptable toxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Carboplatin; Cyclophosphamide; Etoposide; Etoposide phosphate; Melphalan; Thiotepa

Criteria

Inclusion Criteria:

• Patients with high-risk neuroblastoma

• Patients with intermediate-risk neuroblastoma if gross tumor remained after surgery

Exclusion Criteria:

• Patients with progressive disease before high-dose chemotherapy

• Patients whose parents want to stop or change the planned treatment

• Patients with organ toxicities of NCI grade >2 before high-dose chemotherapy